Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing.

Mogensen MB, Rossing M, Østrup O, Larsen PN, Heiberg Engel PJ, Jørgensen LN, Hogdall EV, Eriksen J, Ibsen P, Jess P, Grauslund M, Nielsen HJ, Nielsen FC, Vainer B, Osterlind K.

BMC Cancer. 2018 Jul 20;18(1):752. doi: 10.1186/s12885-018-4639-4.

2.

Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study.

Kringelbach TM, Glintborg B, Hogdall EV, Johansen JS, Hetland ML; Biomarker Protocol Study Group.

BMJ Open. 2018 Feb 1;8(2):e019325. doi: 10.1136/bmjopen-2017-019325.

3.

Annexin A2 and cancer: A systematic review.

Christensen MV, Høgdall CK, Jochumsen KM, Høgdall EVS.

Int J Oncol. 2018 Jan;52(1):5-18. doi: 10.3892/ijo.2017.4197. Epub 2017 Nov 8. Review.

PMID:
29115416
4.

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.

Palshof JA, Høgdall EV, Poulsen TS, Linnemann D, Jensen BV, Pfeiffer P, Tarpgaard LS, Brünner N, Stenvang J, Yilmaz M, Nielsen DL.

BMC Cancer. 2017 Jan 11;17(1):48. doi: 10.1186/s12885-016-3001-y.

5.

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.

Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB, Minlikeeva A, Joseph JM, Mayor P, Abrams SI, Segal BH, Wallace PK, Soh KT, Zsiros E, Anton-Culver H, Bandera EV, Beckmann MW, Berchuck A, Bjorge L, Bruegl A, Campbell IG, Campbell SP, Chenevix-Trench G, Cramer DW, Dansonka-Mieszkowska A, Dao F, Diergaarde B, Doerk T, Doherty JA, du Bois A, Eccles D, Engelholm SA, Fasching PA, Gayther SA, Gentry-Maharaj A, Glasspool RM, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hillemmanns P, Høgdall C, Høgdall EV, Huzarski T, Jensen A, Johnatty SE, Jung A, Karlan BY, Klapdor R, Kluz T, Konopka B, Kjær SK, Kupryjanczyk J, Lambrechts D, Lester J, Lubiński J, Levine DA, Lundvall L, McGuire V, McNeish IA, Menon U, Modugno F, Ness RB, Orsulic S, Paul J, Pearce CL, Pejovic T, Pharoah P, Ramus SJ, Rothstein J, Rossing MA, Rübner M, Schildkraut JM, Schmalfeldt B, Schwaab I, Siddiqui N, Sieh W, Sobiczewski P, Song H, Terry KL, Van Nieuwenhuysen E, Vanderstichele A, Vergote I, Walsh CS, Webb PM, Wentzensen N, Whittemore AS, Wu AH, Ziogas A, Odunsi K, Chang-Claude J, Goode EL, Moysich KB; Australian Ovarian Cancer Study.

Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):420-424. doi: 10.1158/1055-9965.EPI-16-0631. Epub 2016 Sep 27.

6.

Serum YKL-40 and gestational diabetes - an observational cohort study.

Gybel-Brask D, Johansen JS, Christiansen IJ, Skibsted L, Høgdall EV.

APMIS. 2016 Sep;124(9):770-5. doi: 10.1111/apm.12573. Epub 2016 Jul 25.

PMID:
27457220
7.

MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability.

Boisen MK, Dehlendorff C, Linnemann D, Schultz NA, Jensen BV, Høgdall EV, Johansen JS.

BMC Cancer. 2015 Dec 29;15:1024. doi: 10.1186/s12885-015-2030-2.

8.

A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.

Karlsen MA, Høgdall EV, Christensen IJ, Borgfeldt C, Kalapotharakos G, Zdrazilova-Dubska L, Chovanec J, Lok CA, Stiekema A, Mutz-Dehbalaie I, Rosenthal AN, Moore EK, Schodin BA, Sumpaico WW, Sundfeldt K, Kristjansdottir B, Zapardiel I, Høgdall CK.

Gynecol Oncol. 2015 Sep;138(3):640-6. doi: 10.1016/j.ygyno.2015.06.021. Epub 2015 Jun 16.

PMID:
26086566
9.

Tetranectin positive expression in tumour tissue leads to longer survival in Danish women with ovarian cancer. Results from the 'Malova' ovarian cancer study.

Heeran MC, Rask L, Høgdall CK, Kjaer SK, Christensen L, Jensen A, Blaakaer J, Jarle Christensen IB, Høgdall EV.

APMIS. 2015 May;123(5):401-9. doi: 10.1111/apm.12368. Epub 2015 Apr 4.

PMID:
25846370
10.

Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.

Boisen MK, Dehlendorff C, Linnemann D, Nielsen BS, Larsen JS, Osterlind K, Nielsen SE, Tarpgaard LS, Qvortrup C, Pfeiffer P, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Høgdall EV, Jensen BV, Johansen JS.

PLoS One. 2014 Oct 15;9(10):e109430. doi: 10.1371/journal.pone.0109430. eCollection 2014.

11.

HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review.

Karlsen NS, Karlsen MA, Høgdall CK, Høgdall EV.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2285-95. doi: 10.1158/1055-9965.EPI-14-0447. Epub 2014 Aug 28. Review.

12.

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.

Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S.

Gut. 2015 Jun;64(6):921-8. doi: 10.1136/gutjnl-2014-307234. Epub 2014 Jul 10.

PMID:
25011934
13.

CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.

Skougaard K, Johannesen HH, Nielsen D, Schou JV, Jensen BV, Høgdall EV, Hendel HW.

Cancer Med. 2014 Oct;3(5):1294-301. doi: 10.1002/cam4.271. Epub 2014 Jun 18.

14.

Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer.

Sandhu N, Karlsen MA, Høgdall C, Laursen IA, Christensen IJ, Høgdall EV.

Scand J Clin Lab Invest. 2014 Sep;74(6):477-84. doi: 10.3109/00365513.2014.903430. Epub 2014 Apr 13.

PMID:
24724578
15.

Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.

Heeran MC, Høgdall CK, Kjaer SK, Christensen L, Jensen A, Blaakaer J, Christensen IJ, Høgdall EV.

APMIS. 2013 Dec;121(12):1177-86. doi: 10.1111/apm.12071. Epub 2013 Apr 18.

PMID:
23594232
16.

Is tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic?

Sparholt MH, Høgdall CK, Nedergaard L, Heeran MC, Christensen IJ, Høgdall EV.

APMIS. 2013 Jan;121(1):38-44. doi: 10.1111/j.1600-0463.2012.02943.x. Epub 2012 Jul 21.

PMID:
23030299
17.

Limited prognostic value of tissue protein expression levels of cyclin E in Danish ovarian cancer patients: from the Danish 'MALOVA' ovarian cancer study.

Heeran MC, Høgdall CK, Kjaer SK, Christensen L, Blaakaer J, Christensen IJ, Hogdall EV.

APMIS. 2012 Oct;120(10):846-54. doi: 10.1111/j.1600-0463.2012.02913.x. Epub 2012 May 10.

PMID:
22958293
18.

Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.

Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.

Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.

PMID:
22835718
19.

Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.

Håkansson F, Høgdall EV, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Høgdall C; DANISH ‘PELVIC MASS’ OVARIAN CANCER STUDY.

Acta Obstet Gynecol Scand. 2012 Apr;91(4):496-502. doi: 10.1111/j.1600-0412.2012.01359.x. Epub 2012 Feb 22.

PMID:
22229703
20.

A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer.

Høgdall C, Fung ET, Christensen IJ, Nedergaard L, Engelholm SA, Petri AL, Risum S, Lundvall L, Yip C, Pedersen AT, Hartwell D, Lomas L, Høgdall EV.

Gynecol Oncol. 2011 Nov;123(2):308-13. doi: 10.1016/j.ygyno.2011.07.018. Epub 2011 Aug 19.

PMID:
21855971
21.

Limited prognostic value of tissue protein expression levels of BCl-2 in Danish ovarian cancer patients: from the Danish 'MALOVA' ovarian cancer study.

Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Christensen IJ, Høgdall CK.

APMIS. 2010 Aug;118(8):557-64. doi: 10.1111/j.1600-0463.2010.02614.x.

PMID:
20666736
22.

Gene expression profiles as prognostic markers in women with ovarian cancer.

Jochumsen KM, Tan Q, Høgdall EV, Høgdall C, Kjaer SK, Blaakaer J, Kruse TA, Mogensen O.

Int J Gynecol Cancer. 2009 Oct;19(7):1205-13. doi: 10.1111/IGC.0b013e3181a3cf55.

PMID:
19823056
23.

Feasibility of serodiagnosis of ovarian cancer by mass spectrometry.

West-Nørager M, Bro R, Marini F, Høgdall EV, Høgdall CK, Nedergaard L, Heegaard NH.

Anal Chem. 2009 Mar 1;81(5):1907-13. doi: 10.1021/ac802293g.

PMID:
19178286
24.

YKL-40 tissue expression and plasma levels in patients with ovarian cancer.

Høgdall EV, Ringsholt M, Høgdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Møller L, Price PA, Christensen LH.

BMC Cancer. 2009 Jan 9;9:8. doi: 10.1186/1471-2407-9-8.

25.

Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish 'MALOVA'ovarian cancer study.

Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Jarle Christensen I, Gayther S, Jacobs IJ, Høgdall CK.

Pathology. 2008 Aug;40(5):487-92. doi: 10.1080/00313020802197889.

PMID:
18604735
26.

Distribution of microsatellite instability in Danish ovarian tumor patients and the prognostic value in ovarian cancer patients.

Begum FD, Høgdall CK, Kjaer SK, Blaakaer J, Christensen L, Ryan A, Jacobs IJ, Høgdall EV.

Oncol Res. 2008;17(1):43-9.

PMID:
18488714
27.

Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas.

Høgdall EV, Christensen L, Høgdall CK, Frederiksen K, Gayther S, Blaakaer J, Jacobs IJ, Kjaer SK.

APMIS. 2008 May;116(5):400-9. doi: 10.1111/j.1600-0463.2008.00917.x.

PMID:
18452430
28.

Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.

Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK.

Oncol Rep. 2007 Nov;18(5):1051-9.

PMID:
17914554
29.

Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.

Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Christensen IJ, Gayther S, Jacobs IJ, Høgdall CK.

Gynecol Oncol. 2007 Aug;106(2):318-24. Epub 2007 May 31.

PMID:
17540436
30.

YKL-40 protein expression in normal adult human tissues--an immunohistochemical study.

Ringsholt M, Høgdall EV, Johansen JS, Price PA, Christensen LH.

J Mol Histol. 2007 Mar;38(1):33-43. Epub 2007 Jan 23. Erratum in: J Mol Histol. 2007 Aug;38(4):373-6.

PMID:
17242979
31.

Do risk factors for epithelial ovarian cancer have an impact on prognosis? Focus on previous pelvic surgery and reproductive variables.

Kjaerbye-Thygesen A, Frederiksen K, Høgdall EV, Høgdall CK, Blaakaer J, Kjaer SK.

Eur J Gynaecol Oncol. 2006;27(5):467-72.

PMID:
17139980
32.

CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.

Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S, Jacobs IJ, Høgdall CK.

Gynecol Oncol. 2007 Mar;104(3):508-15. Epub 2006 Nov 17.

PMID:
17113137
33.

Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics.

West-Nørager M, Kelstrup CD, Schou C, Høgdall EV, Høgdall CK, Heegaard NH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 15;847(1):30-7. Epub 2006 Nov 16.

PMID:
17112795
34.

Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125).

Gronlund B, Høgdall EV, Christensen IJ, Johansen JS, Nørgaard-Pedersen B, Engelholm SA, Høgdall C.

Int J Biol Markers. 2006 Jul-Sep;21(3):141-8.

PMID:
17013795
35.

Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC).

Begum FD, Høgdall EV, Riisbro R, Christensen IJ, Engelholm SA, Jørgensen M, Pedersen BN, Høgdall CK.

APMIS. 2006 Oct;114(10):675-81.

PMID:
17004970
36.

Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study.

Huusom LD, Frederiksen K, Høgdall EV, Glud E, Christensen L, Høgdall CK, Blaakaer J, Kjaer SK.

Cancer Causes Control. 2006 Aug;17(6):821-9.

PMID:
16783610
37.

Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer.

Kjaerbye-Thygesen A, Frederiksen K, Høgdall EV, Glud E, Christensen L, Høgdall CK, Blaakaer J, Kjaer SK.

Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):798-803.

38.

Increased risk of ovarian cancer in integrin beta3 Leu33Pro homozygotes.

Bojesen SE, Kjaer SK, Høgdall EV, Thomsen BL, Høgdall CK, Blaakaer J, Tybjaerg-Hansen A, Nordestgaard BG.

Endocr Relat Cancer. 2005 Dec;12(4):945-52.

39.

P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.

Høgdall EV, Kjaer SK, Blaakaer J, Christensen L, Glud E, Vuust J, Høgdall CK.

Gynecol Oncol. 2006 Jan;100(1):76-82. Epub 2005 Sep 23.

PMID:
16183105
40.

Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma.

Gronlund B, Dehn H, Høgdall CK, Engelholm SA, Jørgensen M, Nørgaard-Pedersen B, Høgdall EV.

Int J Gynecol Cancer. 2005 Sep-Oct;15(5):836-43.

PMID:
16174233
41.

Sample handling for mass spectrometric proteomic investigations of human sera.

West-Nielsen M, Høgdall EV, Marchiori E, Høgdall CK, Schou C, Heegaard NH.

Anal Chem. 2005 Aug 15;77(16):5114-23.

PMID:
16097747
42.

Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?

Gronlund B, Høgdall C, Hilden J, Engelholm SA, Høgdall EV, Hansen HH.

J Clin Oncol. 2004 Oct 15;22(20):4051-8. Epub 2004 Sep 13.

PMID:
15364966
43.

The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.

Begum FD, Høgdall CK, Kjaer SK, Christensen L, Blaakaer J, Bock JE, Glud E, Høyer-Hansen G, Ring-Larsen H, Høgdall EV.

Anticancer Res. 2004 May-Jun;24(3b):1981-5.

44.

Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.

Høgdall EV, Ryan A, Kjaer SK, Blaakaer J, Christensen L, Bock JE, Glud E, Jacobs IJ, Høgdall CK.

Cancer. 2004 Jun 1;100(11):2387-95.

45.

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?

Gronlund B, Hansen HH, Høgdall C, Høgdall EV, Engelholm SA.

Br J Cancer. 2004 Jan 26;90(2):377-82.

46.

Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay.

Holten-Andersen MN, Schrohl AS, Brünner N, Nielsen HJ, Høgdall CK, Høgdall EV.

Int J Biol Markers. 2003 Jul-Sep;18(3):170-6.

PMID:
14535586
47.

Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study.

Høgdall EV, Kjaer SK, Glud E, Christensen L, Blaakaer J, Vuust J, Bock JE, Norgaard-Pedersen B, Hogdall CK.

Anticancer Res. 2003 Jul-Aug;23(4):3397-404.

PMID:
12926080
48.

High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival.

Høgdall EV, Johansen JS, Kjaer SK, Price PA, Christensen L, Blaakaer J, Bock JE, Glud E, Høgdall CK.

Oncol Rep. 2003 Sep-Oct;10(5):1535-8.

PMID:
12883737
49.

Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.

Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Nørgaard-Pedersen B, Høgdall CK.

Cancer. 2003 Jul 1;98(1):66-73.

50.

K-ras alterations in Danish ovarian tumour patients. From the Danish "Malova" Ovarian Cancer study.

Høgdall EV, Høgdall CK, Blaakaer J, Christensen L, Bock JE, Vuust J, Glud E, Kjaer SK; Danish "Malova" Ovarian Cancer Study.

Gynecol Oncol. 2003 Apr;89(1):31-6.

PMID:
12694651

Supplemental Content

Loading ...
Support Center